Aims: [Gd@C82(OH)22]n is a new type of nanoparticle with potent antineoplastic activity and low toxicity compared with traditional drugs. In this study, we explored, for the first time, the effect of [Gd@C82(OH)22]n on the cell cycle using human breast cancer MCF-7 and human umbilical vein endothelial ECV304 cell lines by flow cytometry. Methods: Cell viability was assessed through CCK-8 assay, and MCF-7 tumor-bearing mice were examined after 2 weeks of treatment with [Gd@C82(OH)22]n. Cell cycle-related gene expression was detected by microarray and confirmed by real-time PCR and RNAi. Results: Cell viability studies confirmed that [Gd@C82(OH)22]n inhibits breast cancer effectively with very low toxicity. Flow cytometric data and microarray results reveal that [Gd@C82(OH)22]n mediates G0/G1 arrest in both cell lines by regulating the expression of several genes, such as cyclin D2, cyclin E and CDK4, among others, in the related cell cycle. Conclusion: Results further demonstrated that [Gd@C82(OH)22]n coul...
Endothelial cells have very important functions, one of which is their contribution to regulating molecule and nutrient exchanges between the blood and peripheral tissues. Dysfunction of endothelial cells plays an essential role in the progression of cardiovascular diseases (CVD) such as atherosclerosis and coronary heart disease. With the recent progress of nanotechnology, increasing numbers of studies have focused on the effects of nanoparticles on CVD. In this article, we review the biological characters of endothelial cells, evaluate the impacts of nanoparticles on the behavior and functions of endothelial cells, analyze advantages and disadvantages of various nanoparticles, and discuss potential applications of nanoparticles to CVD treatment.
Chronic myeloid leukemia (CML) is recognized as a classic clonal myeloproliferative disorder. Given the limited treatment options for CML patients in the accelerated phase (AP) and blast phase (BP), there is an evident need to develop new therapeutic strategies. This has the potential to improve outcomes for individuals in the advanced stages of CML. A promising therapeutic target is Wilms’ tumor 1 (WT1), which is highly expressed in BP-CML cells and plays a crucial role in CML progression. In this study, a chemically synthesized nucleus-targeting WT1 antagonistic peptide termed WIP2W was identified. The therapeutic implications of both the peptide and its micellar formulation, M—WIP2W, were evaluated in WT1+ BP-CML cell lines and in mice. The findings indicate that WIP2W can bind specifically to the WT1 protein, inducing cell cycle arrest and notable cytotoxicity in WT1+ BP-CML cells. Moreover, subcutaneous injections of M—WIP2W were observed to significantly enhance intra-tumoral accumulation and to effectively inhibit tumor growth. Thus, WIP2W stands out as a potent and selective WT1 inhibitor, and the M—WIP2W nanoformulation appears promising for the therapeutic treatment of refractory CML as well as other WT1-overexpressing malignant cancers.